New bag design
As part of our commitment to continuous improvement and innovation we are phasing in a change to the clear plastic bags that we pack our products in.
From Monday the 24th April 2013, we will begin changing the colour of the cytotoxic flash in the corner of the bags from yellow to purple.
We are moving away from the use of yellow to come in line with current NPSA guidance on the labelling of spinal (intrathecal), epidural/regional use only products.
Currently, there is no international standard for labels on spinal (intrathecal), epidural or regional devices but the use of the colour yellow is widely used by healthcare manufacturers and practitioners on labels and devices to help reinforce that these products are for a specified route and not for intravenous use.
Ref: Patient Safety Alerts NPSA/2011/PSA001 and NPSA/2009/PSA004B section 1.3 – to see Supporting Information please click here click here.
Yellow is clearly to be reserved for application to spinal (intrathecal), epidural/regional use only products and this change should avoid any possible confusion. We have chosen purple as this is the most prevalent colour in use throughout the supply chain to indicate cytotoxic substances.
The first new products will be shipped this week with the first new bags arriving with customers from the 25th April. The change will take around 3 months or so as we work through our stock of bags.
You will also see a further minor change to our transport packaging within that period. The yellow cytotoxic tape we currently apply to the top of our boxes will be switched to a purple label across the seal of the top flap.
As usual if you have any questions then please contact your account manager.
Our latest thinking in label design
These changes are limited to the format of the label and font sizes. We have tried to keep essential information grouped together in separate panels so that specific information is not mixed up.
One of the other clear recommendations from the NPSA “Guide on the labelling and packaging of Injectable medicines” (Page 20-23) is that the total quantity in total volume is expressed and emphasised.
We have tried to do this through a clear panel on the top of the label and this is emphasised by using larger and bolder font sizes. All font sizes used have been tested and were determined to be easily readable.
We have avoided continually adding erroneous information and displaying in font size 6.
These changes will initially happen with all batch chemotherapy products and some CIVAS lines and will be phased in over the next four weeks throughout late July 2010 and early August 2010.
These changes will address the judicious use of colour, inclusion of barcodes, improved secondary packaging labels etc.
The second phase began implementation in November 2010 and is scheduled to be completed by April 2011.
If you have been considering these issues recently then Bath ASU would welcome your input.